Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)
- Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 60 participantsVery low
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease events compared with lower PUFA (moderate certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in stroke compared with lower PUFA (low certainty).
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular mortality compared with lower PUFA (low certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in cardiovascular events compared with lower PUFA (moderate certainty).
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in coronary heart disease mortality compared with lower PUFA (low certainty).
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes atrial fibrillation and arrhythmias compared with lower PUFA (very low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).